Objective To compare the eBcacy of three diCerent doses groups A to D, respectively. The diCerences were statistically significant only between groups A and C of intravesical interferon a-2b P<0.001). The results were always in favour of the patients treated with the high dose, the only exception bimonthly for the next 4 months and thereafter monthly for 6 months. The patients were followed for being the diCerence between groups C and D (P= 0.026). No side-eCects of the drug were noted, nor 36 months. The four groups were compared for the number of recurrences (simple recurrence rate), prowas any adverse reaction reported from any patient. Conclusion These results show a significant advantage gression in stage, disease-free interval and recurrence rate per 100 patient-months.for adjuvant intravesical IFNa-2b treatment over TUR alone for the 36 months of follow up and indicate Results During the follow-up, 33 patients had recurrence (13, eight, seven and five in groups A to D, that IFNa-2b can modify the clinical course of superficial TCC at least in the short term. The appropriate respectively). The simple recurrence rate was 65% for group A, compared with 36% (P=0.06), 29% dose was apparently 80 MU, for although 40 MU was better than TUR alone, it was less eCective than 60 (P<0.05) and 22% (P<0.01) for groups B, C and D, respectively. The diCerences in simple recurrence rates MU and 80 MU; the 80 MU dose was slightly better than 60 MU and thus this regimen is recommended. between the groups treated with IFNa-2b were not statistically significant. Eleven patients experienced Keywords Interferon, transitional cell carcinoma, immunotherapy, progression, outcome progression in stage, with six, three, one and one in gression occurs in 5-30% of all cases and up to 80% of